Glucagon-Like Peptide 1 (GLP-1) Agonists Market Regional Analysis Report: Segmentation, Investment Opportunities

The glucagon-like peptide 1 (GLP-1) agonists is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the glucagon-like peptide 1 (GLP-1) agonists market was valued at 12.55 billion in 2021 and is likely to reach USD 20.15 billion by 2029, and will grow at a CAGR of 6.10% during the forecast period of 2022 to 2029.

Full access report:

https://www.databridgemarketresearch.com/reports/global-glucagon-like-peptide-1-glp-1-agonists-market

Top trending reports:

https://marketingofreport.wordpress.com/2024/03/06/glucagon-like-peptide-1-glp-1-agonists-market-regional-analysis-report-segmentation-investment-opportunities/

https://1234submission1234.blogspot.com/2024/03/hospital-air-purifiers-market-detailed.html

https://marketingofreport.wordpress.com/2024/03/06/hospital-air-purifiers-market-detailed-analysis-of-top-ventures-with-regional-outlook/

Drivers

Major factors that are expected to boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the forecast period are as follows:

Rise in the cases of type 2 diabetes, obesity and related disorders
The overall influence of individual-level factors, such as the population's increasing median age and health factors, such as rising obesity and inactivity rates among people, has resulted in an increase in the diabetes population over time.

Growing adaptation of unhealthy lifestyle and genetic history of diabetes disorders
Rise in the hectic lifestyle and unbalanced food diet and the hereditary history of diabetes disorders which upsurges the danger of growing diabetes.

Sample report here:

https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-glucagon-like-peptide-1-glp-1-agonists-market

Recent Development

In November 2021, the Preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors was presented at ObesityWeek 2021, according to Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.

Some of the major players operating in the glucagon-like peptide 1 (GLP-1) agonists market are:

Lilly (US)
Novo Nordisk A/S (Denmark)
AstraZeneca (US)
Sanofi (US)

Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.